Core Viewpoint - Aimer (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution in 2% and 5% concentrations, which are non-prescription dermatological medications [1] Group 1 - The 2% formulation is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% formulation is restricted for use by males only, also for the treatment of androgenetic alopecia and alopecia areata [1] - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in male patients suffering from androgenetic alopecia and alopecia areata [1]

Core Viewpoint - Aimeike (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd. (referred to as "Nobot"), has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution in 2% and 5% concentrations, which are non-prescription dermatological medications [1] Group 1 - The 2% concentration is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% concentration is restricted for use in males only, specifically for treating androgenetic alopecia and alopecia areata [1] - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in patients with androgenetic alopecia and alopecia areata [1]

Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]

Core Viewpoint - The company, Aimeike (300896.SZ), announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution in 2% and 5% concentrations, which are non-prescription dermatological medications [1] Group 1: Product Details - The 2% concentration is intended for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% concentration is restricted for use by males only, also for the treatment of androgenetic alopecia and alopecia areata [1] - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in patients with androgenetic alopecia and alopecia areata [1]

Core Viewpoint - Aimer's subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for Minoxidil topical solution, which is a non-prescription dermatological medication [1] Group 1: Product Approval - The approved Minoxidil topical solution comes in two concentrations: 2% and 5% [1] - The 2% formulation is indicated for the treatment of male pattern hair loss and alopecia areata [1] - The 5% formulation is restricted for use by males only, also for treating male pattern hair loss and alopecia areata [1] Group 2: Product Functionality - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in patients with male pattern hair loss and alopecia areata [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the Minoxidil topical solution registration certificate, indicating a significant development in its product offerings in the dermatology sector [1] Group 1 - The Minoxidil topical solution is classified as a non-prescription dermatological medication [1] - The 2% formulation is intended for the treatment of male pattern hair loss and alopecia areata [1] - The 5% formulation is restricted for male use only, specifically for treating male pattern hair loss and alopecia areata [1]

Group 1 - Aimeike's subsidiary, Beijing Nobot Biotechnology Co., Ltd., received approval from the National Medical Products Administration for Minoxidil topical solution with specifications of 2% and 5% [1] - For the year 2024, Aimeike's revenue composition is projected to be 99.9% from the medical device industry and 0.1% from other industries [1] - Aimeike's market capitalization is currently valued at 55.1 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]

Core Viewpoint - Aimeike (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., received the drug registration certificate for Minoxidil topical solution from the National Medical Products Administration [1] Group 1: Product Details - The Minoxidil topical solution is available in two specifications: 2% and 5% [1] - The 2% specification is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% specification is restricted for use in males only, specifically for treating androgenetic alopecia and alopecia areata [1]

证券代码：300896 证券简称：爱美客 公告编号：2025-042 号 爱美客技术发展股份有限公司 关于全资子公司取得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，爱美客技术发展股份有限公司(以下简称"公司")全资子公司北京诺 博特生物科技有限公司(以下简称"诺博特")收到国家药品监督管理局核准签发 的规格分别为 2%和 5%的米诺地尔搽剂《药品注册证书》，具体情况如下： | 药品名称 | 米诺地尔搽剂 | | | --- | --- | --- | | 生产企业 | 江苏知原药业股份有限公司 | | | 申请事项 | 药品注册（境内生产） | | | 剂型 | 搽剂 | | | 规格 | 2%（60 毫升︰1.2 克） | | | | 克） 5%（60 毫升︰3.0 | | | 注册分类 | 化学药品 类 | 3 | | 药品批准文号 | 2%：国药准字 H20255542 | | | | 5%：国药准字 H20255541 | | | 药品批准文号有效期 | 至 2030 09 月 22 日 | 年 | | 证书编号 | 2% ...

Core Insights - The medical beauty sector experienced a slight increase of 0.36% on September 29, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Beauty Sector Performance - Huaxi Biological (688363) closed at 55.02, with a gain of 0.86% and a trading volume of 26,100 shares, amounting to a transaction value of 142 million yuan [1] - *ST Meigu (000615) closed at 3.28, up 0.61%, with a trading volume of 123,800 shares and a transaction value of 40.03 million yuan [1] - Aimeike (300896) closed at 182.20, down 0.01%, with a trading volume of 26,700 shares and a transaction value of 481 million yuan [1] - Jinbo Biological (832982) closed at 284.30, down 0.65%, with a trading volume of 4,900 shares and a transaction value of 140 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 21.53 million yuan from institutional investors and a net outflow of 12.84 million yuan from speculative funds, while retail investors had a net inflow of 34.37 million yuan [1] - Huaxi Biological had a net inflow of 1.59 million yuan from institutional investors, while it experienced a net outflow of 4.76 million yuan from speculative funds [2] - Aimeike faced a significant net outflow of 22.60 million yuan from institutional investors, but retail investors contributed a net inflow of 29.07 million yuan [2]